

Claims 1, 46, and 56 are amended:

1. (Thrice amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises
- (a) introducing one or more packaging vectors into a fully human serum-resistant non-primate mammalian cell line, wherein said cell line exhibits no specific hybridization to a Moloney-MLV retrovirus *gag-pol* or *env* probe and is capable of producing human-serum-resistant RVP, and wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and
- (b) recovering said packaging cell line.

46. (Twice amended) A method for preparing a stable, retroviral packaging cell line for generation of human serum-resistant retroviral particles (RVP) which comprises
- (a) introducing one or more packaging vectors into a non-primate mammalian cell that is human serum resistant in 100% human serum, wherein said vectors, either singly or collectively, express a cellular targeting protein and retroviral *gag* and *pol* genes in amounts sufficient to package said RVP; and
- (b) recovering said packaging cell line.

56. (Amended) A method for preparing human serum-resistant retroviral vector particles (RVP) which comprises:
- (a) introducing a retrovirus vector into the packaging cell line of Claim 46, wherein said retrovirus vector is capable of being packaged into an RVP and comprises a heterologous gene capable of expression in a human;
- (b) culturing said cell line for a time and under conditions sufficient to produce said RVP; and
- (c) recovering said RVP.